Why the study?
Preexisting immunity can impair AdV-based vector efficacy, making the characterization of different AdV types essential for developing vectors that allow immunization despite anti-AdV immunity.
Does Ad48-based vector immunization improve control of FV infection compared to Ad5-based vector in highly FV-susceptible mice?
Does Ad48-based vector immunization improve control of FV infection compared to Ad5-based vector in highly FV-susceptible mice?
Switching adenovirus vector types (e.g., Ad5 to Ad48) may not be sufficient to circumvent preexisting anti-AdV immunity due to cross-reactivity of humoral and cellular immune responses.
May inform AdV vector selection amid seroprevalence barriers; leaves open optimal designs for broad vaccine efficacy.
AdV-based vectors are important tools for the development of vaccines against a wide range of pathogens. While AdV vectors are generally considered safe and highly effective, their application can be severely impaired by preexisting immunity due to the widespread seroprevalence of some AdV types. The characterization of different AdV types with regard to immunogenicity and efficacy in challenge models is of great importance for the development of improved AdV-based vectors that allow for efficient immunization despite anti-AdV immunity. We show that the immunity induced by an Ad48-based vector is inferior to that induced by an Ad5-based vector but can still mediate the control of an FV infection in highly FV-susceptible mice. However, the efficacy of Ad48-based immunization was impaired in Ad5-preimmune mice. Importantly, we found cross-reactivity of both the humoral and cellular immune responses raised by the individual AdV types, suggesting that switching to a different AdV type may not be sufficient to circumvent preexisting anti-AdV immunity.
No takes yet. Share an insight, caveat, or question.
Hrycak et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: